These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12110251)

  • 1. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years.
    Nichol KL; Goodman M
    Vaccine; 2002 May; 20 Suppl 2():S21-4. PubMed ID: 12110251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
    Nichol KL
    Arch Intern Med; 2001 Mar; 161(5):749-59. PubMed ID: 11231710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization.
    Mullooly JP; Bennett MD; Hornbrook MC; Barker WH; Williams WW; Patriarca PA; Rhodes PH
    Ann Intern Med; 1994 Dec; 121(12):947-52. PubMed ID: 7978721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.
    Nichol KL; Margolis KL; Wuorenma J; Von Sternberg T
    N Engl J Med; 1994 Sep; 331(12):778-84. PubMed ID: 8065407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons.
    Nichol KL; Nordin J; Mullooly J
    Vaccine; 2006 Mar; 24(10):1562-8. PubMed ID: 16300868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.
    Nichol KL; Goodman M
    Pharmacoeconomics; 1999; 16 Suppl 1():63-71. PubMed ID: 10623378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.
    Carias C; Reed C; Kim IK; Foppa IM; Biggerstaff M; Meltzer MI; Finelli L; Swerdlow DL
    PLoS One; 2015; 10(7):e0132922. PubMed ID: 26230271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations.
    Gatwood J; Meltzer MI; Messonnier M; Ortega-Sanchez IR; Balkrishnan R; Prosser LA
    Drugs; 2012 Jan; 72(1):35-48. PubMed ID: 22191794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease.
    van Aalst R; Russo EM; Neupane N; Mahmud SM; Mor V; Wilschut J; Chit A; Postma M; Young-Xu Y
    Vaccine; 2019 Jul; 37(32):4499-4503. PubMed ID: 31262590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.
    Lee PY; Matchar DB; Clements DA; Huber J; Hamilton JD; Peterson ED
    Ann Intern Med; 2002 Aug; 137(4):225-31. PubMed ID: 12186512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.
    Bridges CB; Thompson WW; Meltzer MI; Reeve GR; Talamonti WJ; Cox NJ; Lilac HA; Hall H; Klimov A; Fukuda K
    JAMA; 2000 Oct; 284(13):1655-63. PubMed ID: 11015795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of influenza vaccine in the elderly.
    Nichol KL; Margolis KL; Wouremna J; von Sternberg T
    Gerontology; 1996; 42(5):274-9. PubMed ID: 8940650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.
    Postma MJ; Jansema P; van Genugten ML; Heijnen ML; Jager JC; de Jong-van den Berg LT
    Drugs; 2002; 62(7):1013-24. PubMed ID: 11985488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
    Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus: results from a pilot study.
    Pisu M; Meltzer MI; Hurwitz ES; Haber M
    Pharmacoeconomics; 2005; 23(1):55-67. PubMed ID: 15693728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age.
    Turner DA; Wailoo AJ; Cooper NJ; Sutton AJ; Abrams KR; Nicholson KG
    Vaccine; 2006 Feb; 24(7):1035-43. PubMed ID: 16183177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.
    Wood SC; Nguyen VH; Schmidt C
    Pharmacoeconomics; 2000 Aug; 18(2):173-83. PubMed ID: 11067651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.
    Sisk JE; Moskowitz AJ; Whang W; Lin JD; Fedson DS; McBean AM; Plouffe JF; Cetron MS; Butler JC
    JAMA; 1997 Oct 22-29; 278(16):1333-9. PubMed ID: 9343464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of influenza vaccination. Assessment for The Netherlands.
    Postma MJ; Bos JM; van Gennep M; Jager JC; Baltussen R; Sprenger MJ
    Pharmacoeconomics; 1999; 16 Suppl 1():33-40. PubMed ID: 10623374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.